While many existing drugs for T2DM and obesity target the GLP-1R alone, the ability of tirzepatide to act on both incretin receptors seems to provide synergistic or at least additive benefits [18]
They remain damaged, inactive, and potentially immunogenic
The North America GLP-1 receptor agonist market dominated the revenue with 75.46% share in 2025, supported by a high prevalence of metabolic disorders, early adoption of novel therapeutics, and a well-established healthcare infrastructure
Taking the medication for 12-16 weeks and not experiencing weight reduction (ie
Working alongside traditional therapy or medication, our whole-child care can lead to better sleep, emotional balance, consistent focus and a happier, more confident child
The body naturally secretes GH in pulses rather than continuously